GlassScriptPhysician profile
Julie E Stoddard
NPI 1689362998
$5,460.32
in general payments reported to CMS, 2019-2025
21 companies · $837 in 2025
The $837 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $562 · 2024: $4,061 · 2025: $837.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,460.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,460.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,735.60 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $757.45 | 2023-2025 | |
| Lilly USA, LLC | $421.75 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $400.21 | 2023-2025 | |
| Novo Nordisk INC | $336.74 | 2023-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $301.80 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $231.81 | 2023-2025 | Otezla, Repatha, Repatha |
| Kowa Pharmaceuticals America, INC. | $194.77 | 2024-2025 | Zoryve, Livalo |
| Actelion Pharmaceuticals US, INC. | $175.58 | 2023 | Uptravi, Opsumit |
| Sumitomo Pharma America, INC. | $143.84 | 2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.59 | 2024-2025 | Jardiance, Tradjenta, Synjardy |
| Esperion Therapeutics, INC. | $132.91 | 2024 | Nexletol |
| Pfizer INC. | $89.41 | 2024 | |
| Novartis Pharmaceuticals Corporation | $84.14 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $63.38 | 2024-2025 | Caplyta |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $59.86 | 2024 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $54.68 | 2023 | Xarelto |
| Insulet Corporation | $44.77 | 2024 | Omnipod |
| Otsuka America Pharmaceutical, INC. | $40.69 | 2024 | Rexulti |
| Idorsia Pharmaceuticals US INC | $34.43 | 2024 | Quviviq |
| Merck Sharp & Dohme LLC | $17.91 | 2023 | Verquvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Stoddard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.